Trial · NCT02466074
Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis
NCT02466074, Phase 2, Terminated, The University of Texas Health Science Center, Houston; results first posted 2023-03-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis. Trials, record NCT02466074. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02466074
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis
- NCT number
- NCT02466074
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Conditions
- Multiple Sclerosis
- Interventions
- Acetazolamide, Placebo
- First posted
- 2015-06-09
- Last updated
- 2023-04-27
- Results first posted
- 2023-03-01
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change in Global Cerebral Blood Flow | baseline, 24 weeks | Percent change in global cerebral blood flow (CBF) after 24 weeks relative to pre-treatment baseline. Global CBF is determined using magnetic resonance imaging (MRI) methods. The data reported indicate the extent of change in global CBF--the higher the percent change, the greater the increase in global CBF and the better the outcome. |
| Secondary | Percent Change in Tissue Integrity in White Matter (Mean Diffusivity) | baseline, 24 weeks | The data reported indicate the extent of change in white matter integrity as determined using the diffusion tensor imaging-magnetic resonance imaging (DTI-MRI) measure of mean diffusivity. A positive percent change value indicates an increase in mean diffusivity between baseline and 24 weeks, and a higher mean diffusivity value indicates a breakdown in white matter integrity, so the greater the percent change, the greater the breakdown of white matter integrity and the worse the outcome. |
| Secondary | Percent Change in Tissue Integrity in White Matter (Fractional Anisotropy) | baseline, 24 weeks | The data reported indicate the extent of change in white matter integrity as determined using the diffusion tensor imaging-magnetic resonance imaging (DTI-MRI) measure of fractional anisotropy. A negative percent change value indicates a decrease in fractional anisotropy between baseline and 24 weeks, and a lower fractional anisotropy value indicates a breakdown in white matter integrity, so the lower (and more negative) the percent change, the greater the breakdown of white matter integrity and the worse the outcome. |
| Other | Composite Changes in Disability Measures | 1 year | Composite disability for an individual is defined as at least one of the following: a) any decrease in Expanded Disability Status Score (EDSS), b) 20% reduction in time to complete 9-Hole Peg Test (9HPT) for either the dominant or non-dominant hand, c) 20% decrease in Timed 25-Foot Walk (T25FW) or d) a \>= 4-point or 10% improvement in accuracy for Symbol Digit Modalities Test (SDMT). |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change in Global Cerebral Blood Flow | baseline, 24 weeks | No participants were assigned to the placebo arm. | percent change | MEAN |
| SECONDARY | Percent Change in Tissue Integrity in White Matter (Mean Diffusivity) | baseline, 24 weeks | No participants were assigned to the placebo arm. | percent change | MEAN |
| SECONDARY | Percent Change in Tissue Integrity in White Matter (Fractional Anisotropy) | baseline, 24 weeks | No participants were assigned to the placebo arm. | percent change | MEAN |
| OTHER_PRE_SPECIFIED | Composite Changes in Disability Measures | 1 year |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Global Cerebral Blood Flow | Acetazolamide | 22.9 | Standard Deviation 16.2 | percent change | |
| Percent Change in Tissue Integrity in White Matter (Mean Diffusivity) | Acetazolamide | 1.9 | Standard Deviation 1.3 | percent change | |
| Percent Change in Tissue Integrity in White Matter (Fractional Anisotropy) | Acetazolamide | -2.8 | Standard Deviation 2.4 | percent change |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Acetazolamide | 5 | |
| Overall Study | STARTED | Placebo | 0 | |
| Overall Study | COMPLETED | Acetazolamide | 5 | |
| Overall Study | COMPLETED | Placebo | 0 | |
| Overall Study | NOT COMPLETED | Acetazolamide | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Acetazolamide | 0 | 5 |
| Total, all-cause mortality | Placebo | 0 | 0 |
| Total, other adverse events | Acetazolamide | 0 | 5 |
| Total, other adverse events | Placebo | 0 | 0 |
| Total, serious adverse events | Acetazolamide | 0 | 5 |
| Total, serious adverse events | Placebo | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Symbol Coding | Other outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02466074
GET https://conductscience.org/api/trials/v1/NCT02466074/registered